Promising Umbralisib Combinations Tested in Non-Hodgkin Lymphoma Subtypes
June 26th 2018The phase IIb UNITY-NHL clinical trial (NCT02793583) aims to determine whether the novel drug umbralisib (TGR-1202) could be used as monotherapy or in combination with other drugs to treat patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Trial Combines Selinexor With Standard Therapy in Multiple Myeloma
June 21st 2018Selinexor (KPT-330), a promising drug that retards cell malignancy by blocking the transport of tumor-suppressor proteins out of the cell nucleus, is under investigation as combination therapy in heavily pretreated patients with relapsed/refractory multiple myeloma.
Nurse Trust Among Patients With Ports
June 20th 2018Research has shown that pain and anxiety are related to port access, so a need exists to capture patients’ feelings and emotions related to living with a port, as well as effective nursing interventions aimed at addressing those patient experiences.